At CIC bioGUNE, we are committed to advancing Precision and Personalized Medicine by unraveling the molecular mechanisms underlying diseases, with a multidisciplinary and synergistic spirit. Our research is structured around two main Strategic Research Programs: Molecular Recognition and Host-Pathogen Interactions and Metabolism and Cell Signaling in Disease. They are intimately linked through transversal actions on Precision Medicine and Translational Oncology.

Our research groups bring together a diverse and dynamic community of scientists and technicians, spanning all stages of the scientific career. From Early-Career Researchers to consolidated Group Leaders and Associated Principal Investigators to our Emerging Scientists, CIC bioGUNE fosters scientific excellence and innovation to promote the translation of our scientific results into biotechnological and pharmacological applications. Our multidisciplinary teams explore a broad spectrum of research areas, ranging from chemical and synthetic biology to biomedicine. Our work encompasses key topics such as cell growth and differentiation, cancer, innate immune responses, liver diseases, the design and structural characterization of native and new proteins, and infection mechanisms involving bacteria and viruses.

• Molecular Recognition and Host-Pathogen Interactions

  We investigate cellular processes and pathogenic mechanisms related to cancer cells, viruses, bacteria, and prions. Our goal is to understand immune responses against cancer and develop innovative technologies to combat them. Additionally, we explore how infectious microorganisms interact with mammalian cells, modulating host responses to improve treatment strategies. To achieve this, we employ a synergistic combination of (bio)chemical, cellular, molecular, and structural tools, state-of-the-art methodologies and approaches.

• Metabolism and Cell Signaling in Disease

  Our research focuses on metabolic and signaling pathways involved in cancer, neurodegenerative disorders, liver diseases, and rare diseases. We aim to identify key molecular and cellular targets for more precise therapeutic interventions. Moreover, our teams work on developing predictive and prognostic non-invasive biomarkers to provide Society with innovative tools for early diagnosis and treatment monitoring.